Warfarin-induced skin necrosis.
There is a lack of guidelines regarding the selection of patients who need intravenous heparin, duration of intravenous heparin, and future use of warfarin in prevention and treatment of warfarin-induced skin necrosis. This case report emphasizes the challenges in dealing with vitamin K antagonists (VKA) therapy.
Inayatullah
Seema
S
MeritCare Health System, Department of Internal Medicine, University of North Dakota School of Medicine, Fargo, ND, USA.
Phadke
Gautam
G
Vilenski
Leonid
L
Pasya
Suresh Kumar
SK
Albrecht
Warren
W
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects*; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009336:Necrosis / Q000139:chemically induced; D012867:Skin / Q000473:pathology*; D018746:Systemic Inflammatory Response Syndrome / Q000150:complications*; D019851:Thrombophilia / Q000150:complications; D014813:Vitamin K Deficiency / Q000139:chemically induced* / Q000150:complications; D014859:Warfarin / Q000009:adverse effects*
D000925:Anticoagulants; D014859:Warfarin; D006493:Heparin